862,210 Shares in Illumina, Inc. $ILMN Bought by PointState Capital LP

PointState Capital LP purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 862,210 shares of the life sciences company’s stock, valued at approximately $151,602,000. Illumina makes up about 1.9% of PointState Capital LP’s portfolio, making the stock its 15th largest holding. PointState Capital LP owned approximately 0.57% of Illumina as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Illumina in the second quarter worth approximately $3,374,423,000. Primecap Management Co. CA bought a new position in Illumina during the second quarter valued at $617,981,000. Jupiter Topco LLC bought a new position in shares of Illumina during the 2nd quarter valued at approximately $358,652,000. WCM Investment Management LLC lifted its stake in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Illumina during the second quarter valued at $293,846,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 0.1%

Shares of ILMN opened at $224.84 on Thursday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $227.70. The firm has a market capitalization of $33.95 billion, a P/E ratio of 41.95, a P/E/G ratio of 3.17 and a beta of 1.45. The firm has a 50-day moving average price of $191.66 and a 200 day moving average price of $154.42. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period last year, the business earned $1.19 earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on ILMN shares. TD Cowen increased their price target on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Guggenheim boosted their price target on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Finally, Royal Bank Of Canada lifted their target price on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $188.40.

Insider Buying and Selling at Illumina

In other news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the sale, the insider owned 20,338 shares of the company’s stock, valued at $4,067,600. The trade was a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the transaction, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,874,458 shares of company stock worth $367,996,424 over the last three months. 2.90% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.